6 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 6 of 6 clinical reviews.
A critical analysis of the STEP-2 semaglutide trial in type 2 diabetes, covering enrollment biases, generalizability gaps, statistical caveats, conflict-of-interest disclosures, and post-publication commentary.
Deep-dive into published cost-effectiveness analyses of semaglutide 2.4 mg from the STEP-2 trial in type 2 diabetes, including cost per QALY, payer coverage, and real-world pricing.
Complete breakdown of the STEP-2 trial results for semaglutide 2.4 mg in type 2 diabetes, including primary and secondary endpoints, confidence intervals, response distribution, and time-course data.
Deep-dive into STEP-2 pre-specified and post-hoc subgroup analyses for semaglutide 2.4 mg in type 2 diabetes, examining differential weight loss by age, sex, BMI, race, and baseline biomarkers.
A deep-dive overview of the STEP-2 randomized controlled trial testing semaglutide 2.4 mg for weight loss in adults with type 2 diabetes, including methodology, results, limitations, and clinical implications.
How the STEP-2 trial reshaped prescribing for semaglutide 2.4 mg in type 2 diabetes, which guidelines responded, and what clinicians should consider for patients outside the trial population.